Novartis shares drop after del-desiran misses trial endpoint
Novartis stock fell 10.1% to $138.51 after del-desiran missed the primary endpoint in a myotonic-dystrophy trial, The move erased about CHF24 billion in market value.
Novartis NYSE:NVS, the Swiss pharmaceutical giant, absorbed a sharp setback Tuesday after del-desiran missed the primary endpoint in a pivotal myotonic-dystrophy trial. 51, wiping about CHF24 billion from the company’s market value,